Conclusion Collateral grade, NIHSS score at presentation, and number of passes are independent predictors of unfavorable outcomes at 90 days.

Disclosures A. Siddiqui: 1; C; Co-investigator NIH/NINDS 1R01NS091075. 2; C; Canon Medical System US, Boston Scientific, Amnis Therapeutics, Cerebrotech Medical Systems, Silk Road, Corindus Inc., Blockade Medical, Guidepoint Global Consulting, Imperative Care, Integra LifeSciences Corp, Medtronic, MicroVention, Q'Apel Medical Inc, Rapid Medical, Rebound Therapeutics Corp., Serenity Medical Inc, Silk Road Medical, StimMed, Stryker, Three Rivers Medical, VasSol, W. L. Gore & Associates. M. Waqas: None. T. Andersson: 2; C; Neuravi, Ablynx, Amnis Therapeutics, Medtronic, Rapid Medical, Stryker. J. Saver: 1; C; Medtronic-Abbott, Neuravi. H. Mattle: None. H. Bozorgchami: None. R. Chapot: None. A. Narata: None. A. Yoo: 1; C; Penumbra, Neuravi, Cerenovus. M. Ribo: None. O. Zaidat: 2; C; Stryker, Medtronic, Neuravi, Penumbra.

0-003 PREDICTORS OF SUCCESSFUL REVASCULARIZATION IN THE ARISE II STUDY

¹A Jadhav*, ¹S Desai, ²D Liebeskind, ³A Yoo, ⁴H Bozorgchami, ⁵M Ribo, ²JL Saver, ⁶H Mattle, ⁷T Andersson, ⁸O Zaidat. ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of California Los Angeles, Los Angeles, CA; ³Texas Stroke Institute, Plano, TX; ⁴Oregon Health and Science University, Portland, OR; ⁵Hospital Vall d'Hebron, Barcelona, SPAIN; ⁶Neurologische Universitätsklinik, Inselspital, Bern, SWITZERLAND; ⁷AZ Groeninge, Kortrijk, BELGIUM; ⁸Neuroscience Institute, Mercy Health St. Vincent Medical Center, Toledo, OH

10.1136/neurintsurg-2019-SNIS.3

Introduction Swift and complete revascularization in large vessel occlusion (LVO) stroke is associated with better functional outcomes. First pass effect (FPE), achievement of TICI 2C/3 revascularization on the first pass, is a new metric of technical success of endovascular thrombectomy (EVT). We aim to identify predictors of FPE and TICI 3 revascularization in the ARISE II study.

Methods Anterior circulation LVO [ACLVO-internal carotid (ICA) and middle cerebral artery (MCA-M1)] strokes from the ARISE II study were used for this analysis. Core-lab adjudicated TICI scores after the first pass of EmboTrap were collected. FPE and modified FPE (mFPE) were defined as first pass achievement of TICI 2C/3 and TICI $\geq$ 2B, respectively. Demographic, clinical and radiographic parameters were analyzed. Multivariable logistic regression was performed to identify predictors.

Results A total of 161 ACLVOs underwent thrombectomy in the ARISE II study. Mean age was 67 ± 13 years and 43% (n=69) were male. Mean NIHSS and median ASPECTS were 16 ± 5 and 10, respectively. While FPE was achieved in 37% (n=59), mFPE was seen 43% (n=69) patients. Multivariable logistic regression was performed using age, sex, use of IV-tPA, BMI, NIHSS, vascular risk factors, ASPECTS, collateral status (ASITN), occlusion location and use of balloon-guided catheter as variables. While absence of ICA occlusion (p=0.07, OR-8.6, 0.8–90) can predict FPE, there were no independent predictors of mFPE. Independent predictors of TICI 3 after 3 passes include use of balloon guide catheter (p=0.01, OR-0.033, 0.003–0.535) and higher ASITN score (p=0.04, OR-10.2, 1–100).

Conclusion Absence of internal carotid artery occlusion predicts FPE and the use of balloon guide catheter and favorable collaterals predicts complete revascularization. These results support the consideration of routine BGC use with the Embo-trap device to achieve complete revascularization.

Disclosures A. Jadhav: None. S. Desai: None. D. Liebeskind: None. A. Yoo: None. H. Bozorgchami: None. M. Ribo: None. J. L.: None. H. Mattle: None. T. Andersson: None. O. Zaidat: None.

0-004 CHANGES IN GENE EXPRESSION OF CXCL9 IN INTRACRANIAL DISTAL BLOOD DURING EMERGENT LARGE VESSEL OCCLUSION IN HUMAN STROKE

¹J Fraser*, ²S Martha, ²L Collier, ²S Davis, ³A Alhajeri, ⁴S Grupke, ²K Pennypacker. ¹Neurological Surgery, Neurology, Radiology, and Neuroscience, University of Kentucky, Lexington, KY; ²Neurology, University of Kentucky, Lexington, KY; ³Neurological Surgery, Neurology, and Radiology, University of Kentucky, Lexington, KY; ⁴Neurological Surgery, University of Kentucky, Lexington, KY

10.1136/neurintsurg-2019-SNIS.4

Background and purpose Mechanical thrombectomy (MT) is the standard of care for emergent large vessel occlusion (ELVO), one of the most severe subtypes of ischemic stroke, which accounts for 30–40% of all cases. Through MT, we can isolate distal blood within the artery immediately downstream from the clot and compare it to systemic arterial blood to provide insight into local intraluminal changes during ischemia. CXCL9 is an interferon gamma-inducible chemokine that binds CXCR3, degrading endothelial tight junctions, attracting T cells, and facilitating immune cell extravasation into brain parenchyma. We aimed to study local CXCL9 expression distal to the intracranial thrombus during large vessel occlusion in human patients.

Methods Tissue samples of distal and proximal blood were collected as part of the BACTRAC tissue bank (www.clinicaltrials.gov NCT03153683). Adult subjects with ELVO were prospectively enrolled, and arterial blood distal (intracranial) and proximal (cervical) were collected and processed to optimize RNA quality. RNA were isolated and used to evaluate gene expression in both samples for each subject; proximal systemic blood was used as an internal control for each subject.

Results 22 subjects were included in this preliminary analysis. 15 (68.2%) were female. 54.5% of subjects had a CTA collateral score of 1 (18.2% had a score of 0). 4.5% (1 subject) did not attain TICI 2B or 3 recanalization. Infarct time (last known normal to thrombectomy recanalization) was 491 ± 243 minutes. Mean change in NIHSS from admission to discharge was -8 ± 8 . CXCL9 expression in distal blood was upregulated an average of 106-fold with a maximum upregulation of 805-fold in one subject. In plotting CXCL9 expression against infarct time, there was a clear negative correlation (Spearman coefficient -0.43, p=0.05).

Conclusion For the first time, we evaluate chemokine alterations in human stroke patients in distal stagnant blood during ELVO. There is a significant variance in CXCL9 expression in distal blood in relationship to infarct time, which mirrors the known timing of blood-brain barrier disruption.